InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board
InMed Pharmaceuticals Inc. (NASDAQ: INM) has appointed Dr. Barry Greenberg to its Scientific Advisory Board. Dr. Greenberg is the Director of the Alzheimer's Disease Translational Center and an Associate Professor in the Department of Neurology at the Johns Hopkins University School of Medicine. With four decades of experience in Alzheimer's disease research, Dr. Greenberg's expertise is expected to be invaluable as InMed advances its INM-901 drug candidate towards human clinical trials in Alzheimer's disease.
Dr. Greenberg has held various positions in the US, Sweden, and Canada, including roles at AstraZeneca and Neurochem, Inc. He has been involved in Alzheimer's disease research and drug discovery since 1985 and has contributed to developing strategies to delay the onset and progression of the disease. At Johns Hopkins, he leads the development of an AD Translational Center, focusing on integrating basic and clinical research to enable the development of effective therapies for Alzheimer's disease.
InMed Pharmaceuticals Inc. (NASDAQ: INM) ha nominato Dr. Barry Greenberg nel suo Consiglio Consultivo Scientifico. Il Dr. Greenberg è Direttore del Centro di Traslazione per la Malattia di Alzheimer e Professore Associato nel Dipartimento di Neurologia della Johns Hopkins University School of Medicine. Con quattro decenni di esperienza nella ricerca sulla malattia di Alzheimer, l'esperienza del Dr. Greenberg è attesa come fondamentale mentre InMed porta il suo candidato farmaco INM-901 verso prove cliniche umane per questa malattia.
Il Dr. Greenberg ha ricoperto diverse posizioni negli Stati Uniti, in Svezia e in Canada, inclusi ruoli presso AstraZeneca e Neurochem, Inc. È coinvolto nella ricerca e scoperta di farmaci per la malattia di Alzheimer dal 1985 e ha contribuito allo sviluppo di strategie per ritardare l'insorgenza e la progressione della malattia. Presso la Johns Hopkins, guida lo sviluppo di un Centro di Traslazione per l'AD, concentrandosi sull'integrazione della ricerca di base e clinica per consentire lo sviluppo di terapie efficaci per la malattia di Alzheimer.
InMed Pharmaceuticals Inc. (NASDAQ: INM) ha nombrado al Dr. Barry Greenberg para su Consejo Asesor Científico. El Dr. Greenberg es el Director del Centro de Traducción de la Enfermedad de Alzheimer y Profesor Asociado en el Departamento de Neurología de la Escuela de Medicina de la Universidad Johns Hopkins. Con cuatro décadas de experiencia en la investigación sobre la enfermedad de Alzheimer, se espera que la experiencia del Dr. Greenberg sea invaluable mientras InMed avanza su candidato a medicamento INM-901 hacia ensayos clínicos en humanos para esta enfermedad.
El Dr. Greenberg ha ocupado diversos puestos en EE. UU., Suecia y Canadá, incluidos roles en AstraZeneca y Neurochem, Inc. Ha estado involucrado en la investigación y el descubrimiento de medicamentos para la enfermedad de Alzheimer desde 1985 y ha contribuido al desarrollo de estrategias para retrasar la aparición y progresión de la enfermedad. En Johns Hopkins, lidera el desarrollo de un Centro de Traducción para la DA, enfocándose en integrar la investigación básica y clínica para permitir el desarrollo de terapias efectivas para la enfermedad de Alzheimer.
인메드 제약 주식회사 (NASDAQ: INM)는 박사 벤 리 그린버그를 과학 자문 위원회에 임명했습니다. 그린버그 박사는 알츠하이머 병 이행 센터의 소장으로, 존스 홉킨스 대학교 의과대학 신경과학과의 부교수입니다. 알츠하이머 병 연구에서 40년 이상의 경험을 가진 그린버그 박사의 전문성은 인메드가 INM-901 후보 약물을 알츠하이머 병에 대한 인간 임상 시험으로 나아가는 데 있어 큰 도움이 될 것으로 기대됩니다.
그린버그 박사는 미국, 스웨덴 및 캐나다에서 아스트라제네카와 뉴로켐 주식회사 등 여러 직책에서 활동했습니다. 그는 1985년부터 알츠하이머 병 연구 및 약물 발견에 참여해 왔으며, 질병의 발병 및 진행을 지연시키기 위한 전략 개발에 기여했습니다. 존스 홉킨스에서 그는 기초 연구와 임상 연구를 통합하여 알츠하이머 병 치료제를 개발할 수 있도록 AD 이행 센터의 개발을 이끌고 있습니다.
InMed Pharmaceuticals Inc. (NASDAQ: INM) a nommé Dr. Barry Greenberg à son Conseil Consultatif Scientifique. Le Dr Greenberg est Directeur du Centre de Traduction de la Maladie d'Alzheimer et Professeur Associé au Département de Neurologie de l’École de Médecine de l’Université Johns Hopkins. Fort de quatre décennies d'expérience dans la recherche sur la maladie d'Alzheimer, l'expertise du Dr Greenberg est considérée comme inestimable alors qu'InMed fait progresser son candidat médicament INM-901 vers des essais cliniques humains pour cette maladie.
Le Dr Greenberg a occupé divers postes aux États-Unis, en Suède et au Canada, y compris des rôles chez AstraZeneca et Neurochem, Inc. Il est impliqué dans la recherche sur la maladie d'Alzheimer et la découverte de médicaments depuis 1985 et a contribué au développement de stratégies pour retarder l'apparition et la progression de la maladie. À Johns Hopkins, il dirige le développement d'un Centre de Traduction pour l'AD, en se concentrant sur l'intégration de la recherche fondamentale et clinique pour permettre le développement de thérapies efficaces pour la maladie d'Alzheimer.
InMed Pharmaceuticals Inc. (NASDAQ: INM) hat Dr. Barry Greenberg in sein wissenschaftliches Beratungsgremium berufen. Dr. Greenberg ist Direktor des Translational Centers for Alzheimer’s Disease und außerordentlicher Professor in der Abteilung für Neurologie an der Johns Hopkins University School of Medicine. Mit vier Jahrzehnten Erfahrung in der Alzheimerforschung wird die Expertise von Dr. Greenberg als von unschätzbarem Wert angesehen, während InMed seinen INM-901 Medikamentenkandidaten in Richtung humaner klinischer Studien für Alzheimer vorantreibt.
Dr. Greenberg hat verschiedene Positionen in den USA, Schweden und Kanada innegehabt, darunter Rollen bei AstraZeneca und Neurochem, Inc. Er ist seit 1985 in der Alzheimerforschung und Medikamentenentwicklung tätig und hat zur Entwicklung von Strategien beigetragen, um den Beginn und das Fortschreiten der Krankheit zu verzögern. An der Johns Hopkins leitet er die Entwicklung eines AD-Translational Centers, das sich auf die Integration von Grundlagen- und klinischer Forschung konzentriert, um die Entwicklung effektiver Therapien für Alzheimer zu ermöglichen.
- Appointment of Dr. Barry Greenberg, an expert in Alzheimer's disease research, to the Scientific Advisory Board
- Dr. Greenberg's expertise expected to be valuable for advancing INM-901 drug candidate towards clinical trials
- Strengthening of InMed's scientific advisory team with a renowned expert in neurodegenerative diseases
- None.
Vancouver, British Columbia--(Newsfile Corp. - October 22, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the appointment of Dr. Barry Greenberg to its Scientific Advisory Board. Dr. Greenberg is the Director of the Alzheimer's Disease Translational Center and an Associate Professor in the Department of Neurology at the Johns Hopkins University School of Medicine.
Dr. Eric Hsu, InMed's Senior Vice President of Preclinical Research and Development, stated, "Dr. Barry Greenberg's commitment to Alzheimer's and dementia research has been instrumental in developing strategies to delay the onset and progression of the disease. His four decades of Alzheimer's disease research has also contributed to improved clinical practices and the advancement of new treatments. We are fortunate to have Dr. Greenberg join our Scientific Advisory Board where his expertise and guidance will be invaluable as we advance our INM-901 drug candidate towards human clinical trials in Alzheimer's disease."
Biography of Barry Greenberg, PhD
Barry Greenberg is an Associate Professor in the Department of Neurology and Director of the Alzheimer's Disease Translational Center at the Johns Hopkins University School of Medicine. Dr. Greenberg has been involved in Alzheimer's disease ("AD") research and drug discovery since 1985, holding a series of positions internationally in the US, Sweden and Canada. He was part of a drug discovery team at AstraZeneca leading over 50 individuals from eight departments. He later led the preclinical biology research program at Neurochem, Inc. in Québec as Senior Director of Pharmacology. Dr. Greenberg moved to the University Health Network in Toronto in 2008, as Director of Neuroscience Drug Discovery and Development, where he was responsible for the conceptualization and leadership as Strategy Director of the Toronto Dementia Research Alliance, a collaborative alliance across five research institutes. Additionally, he served as Chair of the National Institute on Aging's international committee, which was charged with strategizing the future structure of the Alzheimer's Disease Research Center ("ADRC") network. Dr. Greenberg moved to Johns Hopkins in 2018 to lead the development of an AD Translational Center, with the objective of integrating basic and clinical research to enable the development of effective therapies that will delay or prevent AD at its earliest stages. He has been involved with the Johns Hopkins ADRC since that time, as a member of its Executive Committee and Co-Leader of its Research Education Component. He serves on several committees and advisory boards for NIA-funded initiatives focused on genetics, model development and clinical trials in AD, and is Editor-in-Chief of the journal "Alzheimer's & Dementia: Translational Research and Clinical Interventions."
Barry Greenberg's Publications
https://pure.johnshopkins.edu/en/persons/barry-greenberg
About InMed's INM-901 for the potential treatment of Alzheimer's disease
INM-901 is a small molecule drug candidate being developed as a potential treatment of Alzheimer's disease. INM-901 demonstrates multiple pharmacological effects in preclinical studies including neuroprotective effects, an ability to extend the length of neurites which is important for brain cell-to-cell communication, as well as a reduction in neuroinflammation. These preclinical studies were conducted in well-characterized study models of Alzheimer's disease.
Learn more about InMed's INM-901 program:
https://www.inmedpharma.com/pharmaceutical/inm-901-for-alzheimers-disease/
About InMed:
InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com.
Investor Contact:
Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1 604 416 0999
E: ir@inmedpharma.com
Cautionary Note Regarding Forward-Looking Information:
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "potential", "possible", "would" and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about: Appointing Dr. Barry Greenberg to InMed's Scientific Advisory Board; the efficacy of INM-901; INM-901’s ability to treat AD and advancing our INM-901 drug candidate towards human clinical trials.
Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission on www.sec.gov.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/227344
FAQ
Who is Dr. Barry Greenberg and why was he appointed to InMed Pharmaceuticals' Scientific Advisory Board?
What is InMed Pharmaceuticals' INM-901 drug candidate targeting?
How might Dr. Barry Greenberg's appointment impact InMed Pharmaceuticals' (NASDAQ: INM) research efforts?
What is Dr. Barry Greenberg's current role at Johns Hopkins University School of Medicine?
